Literature DB >> 17394085

Offers of hepatitis C care do not lead to treatment.

Bruce R Schackman1, Paul A Teixeira, Ann B Beeder.   

Abstract

Since 2002, clinicians have been encouraged to offer chronic hepatitis C virus (HCV) treatment to patients with injection drug use histories. We conducted 69 baseline and 35 follow-up interviews between September 2002 and November 2004 with HCV patients who were treatment-naïve and receiving regular medical care at an HIV or methadone clinic in New York City at baseline. Of the 31 patients reinterviewed, 20 (65%) were offered treatment but only 2 (7%) were treated. Reasons for failure to be reinterviewed were loss to follow-up at the original site of care (30), death (6), and refusal to be reinterviewed (2). Whereas offers of HCV treatment may be increasing, there is a need to improve continuity of care, patient-provider communication, and patient education regarding HCV treatment options for treatment rates to improve.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394085      PMCID: PMC2231831          DOI: 10.1007/s11524-007-9180-8

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  2 in total

1.  The MOS social support survey.

Authors:  C D Sherbourne; A L Stewart
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

2.  Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

  2 in total
  14 in total

1.  Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Authors:  Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais
Journal:  J Subst Abuse Treat       Date:  2012-03-08

2.  A model of patient choice with mid-therapy information.

Authors:  William C Grant; Teresa L Kauf
Journal:  Patient       Date:  2009-09-01       Impact factor: 3.883

3.  Can urban methadone patients complete health utility assessments?

Authors:  Paul A Teixeira; Bruce R Schackman
Journal:  Patient Educ Couns       Date:  2008-03-07

Review 4.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

5.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

6.  Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.

Authors:  Sarah Schaeffer; Mandana Khalili
Journal:  Ann Hepatol       Date:  2015 Mar-Apr       Impact factor: 2.400

7.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

8.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

9.  Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Authors:  Marija Zeremski; Rositsa B Dimova; Roberto Zavala; Steven Kritz; Melissa Lin; Bryce D Smith; Jon E Zibbell; Andrew H Talal
Journal:  J Addict Med       Date:  2014 Jul-Aug       Impact factor: 3.702

Review 10.  Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Authors:  Marija Zeremski; Jon E Zibbell; Anthony D Martinez; Steven Kritz; Bryce D Smith; Andrew H Talal
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.